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Purpose of the study
The high antiviral potency and low toxicity of saquinavir/
ritonavir (SQV/r), prompted us to assess the antiviral effi-
cacy and safety of SQV/r monotherapy as a new mainte-
nance regimen in chronically virological suppressed HIV-
infected patients.
Methods
Pilot, multicenter and randomized trial of 48 weeks fol-
low-up. Patients with undetectable viral load (VL <50 cop-
ies/mL) under a HAART, without history of virological
failure to a PI-based regimen or PI-related resistances were
randomly assigned (2:1) to receive SQV 1000 mg/ritona-
vir 100 mg BID (SQV/r group) or to continue on the same
treatment (control group). They were followed monthly
until week 24 and each 3 months thereafter. Comparison
were performed by the Mann-Whitney test for medians
and by the χ2 or Fisher's exact test for proportions.
Summary of results
A total of 28 patients were randomized: 17 to SQV/r group
and 11 to control group. Only one patient from SQV/r
group experienced a virological failure at week 36. Similar
mean increase in CD4+ cell counts from baseline to week
48 were seen in both groups: +31 cell/mm3 in SQV/r
group and +53 cell/mm3 in control group. Three patients
(10.7%), from SQV/r group, interrupted prematurely the
study for reason other than virological failure (an acute
hepatitis B, a 2-fold increase of transaminases in a VHC
co-infected patient with high baseline levels, and a volun-
tary cessation of therapy). Total cholesterol did not signif-
icantly vary throughout the study in any group (p =
0.794); HDLc showed a significant increase at week 48 in
comparison with the baseline values only in SQV/r group
(from 41 ± 11 mg/dl to 56 ± 35, p = 0.028), while patients
from control group showed a decrease in LDLc (from 129
± 37 mg/dl to 107 ± 17, p = 0.028). Median (IQR) trough
concentrations of SQV in plasma were 760 (379.5–
1332.25). No patient had saquinavir concentrations
lower than 100 ng/mL.
Conclusion
SQV/r monotherapy, administered twice daily, may be a
valid and economic option as a nucleoside-sparing strat-
egy for virologically suppressed HIV-infected patients
without prior history of virologic failure to protease inhib-
itor-containing regimens, especially in those with intoler-
ance or toxicities to nucleosides.
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